Levetiracetam Holsten

Levetiracetam, the active ingredient in Levetiracetam Holsten, is an antiepileptic presented as an oral tablet for oral use. It is used to control partial, generalized tonic‑clonic and myoclonic seizures in patients with epilepsy.

GNH USA supplies Levetiracetam Holsten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable supply chains, transparent documentation, and responsive technical support throughout the procurement process.

Levetiracetam is an antiepileptic medication indicated for several seizure types and is often employed as part of a comprehensive epilepsy management plan.

Partial seizures: reduces the frequency of focal seizure episodes in patients with epilepsy. Generalized tonic‑clonic seizures: helps control convulsive seizures that affect the whole brain. Myoclonic seizures: decreases sudden muscle jerks associated with myoclonic epilepsy. Adjunct therapy: can be combined with other antiepileptic drugs when monotherapy does not achieve seizure control. Adjunctive therapy in refractory epilepsy: offers an alternative mechanism for patients with drug‑resistant seizures.

Levetiracetam may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness that may affect balance. - Somnolence: increased sleepiness or fatigue, especially after dosing, that can impair daily activities. - Headache: mild to moderate head pain, often transient. - Irritability: mood changes including increased agitation or nervousness.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing requiring immediate medical attention. - Stevens‑Johnson syndrome: rare, potentially life‑threatening skin disorder with blistering and mucosal involvement. - Psychiatric disturbances: new or worsening depression, anxiety, aggression, or suicidal thoughts.

When prescribing levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: dose adjustment may be required based on creatinine clearance. - Hepatic dysfunction: monitor liver function tests, especially in patients with existing liver disease. - Psychiatric history: observe for mood changes, depression, or suicidal ideation. - Concomitant CNS depressants: use caution as combined effects may increase sedation. - Pregnancy and lactation: evaluate risk‑benefit ratio; limited data available. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Levetiracetam can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels, decreasing seizure control. - Phenobarbital: can lower levetiracetam concentrations, potentially compromising effectiveness. - Phenytoin: may increase clearance of levetiracetam, leading to sub‑therapeutic exposure.

Moderate Interactions (Monitor Closely): - Sedative agents (e.g., benzodiazepines, alcohol): additive CNS depression may increase drowsiness. - Immunosuppressants (e.g., cyclosporine): monitor levels as levetiracetam may affect metabolism. - Oral contraceptives: levetiracetam may reduce hormonal efficacy; advise alternative contraception.